NCT05893927 Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes
| NCT ID | NCT05893927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Reading Hospital and Medical Center |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 65 participants |
| Start Date | 2024-02-15 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 65 participants in total. It began in 2024-02-15 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the use and effectiveness of a mobile web application (app) that is designed to educate and allow patients to manage diabetes and make sustainable lifestyle changes, and to study the impact of the app on clinical outcomes of diabetes (HA1C) and educational outcomes (Self-Efficacy for Diabetes Scale). The main question to answer is: Does the use of the Diabetes Application significantly affect clinical outcomes of diabetes and cardiometabolic risk factors (BMI and Blood Pressure)? Patients will be enrolled in one of two available arms of the study. Participants in the 'intervention arm' will use the app to view educational information presented as videos in the following areas: Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes and Disease Pathophysiology. They will continue routine follow-up care with their primary care physicians during the study. Participants in the 'control arm' will continue with their primary care physician in routine follow-up care, as normally scheduled. Researchers will compare the intervention arm participants to the control arm participants to find out about and compare changes in HA1C, systolic blood pressure, diastolic blood pressure, and body mass index. Groups will also be compared on the basis of self-perceived confidence of managing their diabetes by way of the Diabetes Self Efficacy Scale.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of Type 2 Diabetes with HA1c \>8.0 * Current patients of the Family Healthcare Center, Reading Hospital Tower health. Exclusion Criteria: * Identified special populations (pregnancy or individuals currently incarcerated) * Patients without access to their own smart phone * Any patient who is unable to provide their own informed consent to participate in the study
Contact & Investigator
Luis A Murillo, MD, MPH
PRINCIPAL INVESTIGATOR
Reading Hospital Tower Health
Frequently Asked Questions
Who can join the NCT05893927 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05893927 currently recruiting?
Yes, NCT05893927 is actively recruiting participants. Contact the research team at mary.alderfer@towerhealth.org for enrollment information.
Where is the NCT05893927 trial being conducted?
This trial is being conducted at West Reading, United States.
Who is sponsoring the NCT05893927 clinical trial?
NCT05893927 is sponsored by The Reading Hospital and Medical Center. The principal investigator is Luis A Murillo, MD, MPH at Reading Hospital Tower Health. The trial plans to enroll 65 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.